Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
Fred Hutchinson Cancer Center
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Thomas Jefferson University
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
Masonic Cancer Center, University of Minnesota
Case Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University
Memorial Sloan Kettering Cancer Center
Therapeutic Advances in Childhood Leukemia Consortium
M.D. Anderson Cancer Center
Northside Hospital, Inc.
Memorial Sloan Kettering Cancer Center
Thomas Jefferson University
University of Liege
H. Lee Moffitt Cancer Center and Research Institute
Icahn School of Medicine at Mount Sinai
Dartmouth-Hitchcock Medical Center
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
University of Illinois at Chicago
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Weill Medical College of Cornell University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Masonic Cancer Center, University of Minnesota
Massachusetts General Hospital
M.D. Anderson Cancer Center
Beth Israel Deaconess Medical Center
University of Chicago
Beth Israel Deaconess Medical Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
King's College Hospital NHS Trust
Indiana University
University of Virginia
Texas Oncology Cancer Center
Targazyme, Inc.
Baylor College of Medicine
M.D. Anderson Cancer Center